InterCure Ltd. (Nasdaq: INCR) has regained compliance with Nasdaq’s minimum bid price requirement for continued listing. The company operates in the digital therapeutics and medical device sectors, focusing on chronic disease management solutions. This compliance follows prior concerns over share price thresholds.
InterCure Ltd secures a **NIS 230 million (~US$77 million) settlement** to address war-related indirect damages. The agreement resolves financial losses incurred by the company due to conflict impacts, covering operational disruptions and supply chain challenges. InterCure operates in the pharmaceutical sector, specializing in medical devices and treatments.
InterCure Ltd. implements a 1-for-5 reverse share split to adjust its stock price. The move aims to improve liquidity and trading volume for its publicly traded shares. The company operates in the life sciences sector, specializing in digital health solutions.
InterCure finalizes the initial phase of its acquisition of Botanico, a company specializing in botanical-based health solutions. The transaction marks a strategic move to expand InterCure’s portfolio in natural wellness products. Botanico’s expertise in plant-derived therapies aligns with InterCure’s focus on innovative healthcare offerings.
